342 related articles for article (PubMed ID: 23986394)
1. Dermatomyositis induced by anti-tumor necrosis factor in a patient with juvenile idiopathic arthritis.
Liu SW; Velez NF; Lam C; Femia A; Granter SR; Townsend HB; Vleugels RA
JAMA Dermatol; 2013 Oct; 149(10):1204-8. PubMed ID: 23986394
[TBL] [Abstract][Full Text] [Related]
2. Secondary syphilis following tumor necrosis factor-α inhibitor treatment for rheumatoid arthritis.
Asahina A; Ishii N; Tohma S
J Dermatol; 2012 Feb; 39(2):199-201. PubMed ID: 21463364
[No Abstract] [Full Text] [Related]
3. Squamous cell carcinoma of the lip associated with adalimumab therapy for ankylosing spondylitis: a case report and review of TNF-α inhibitors and cutaneous carcinoma risk.
Zitelli KB; Zedek D; Ranganathan P; Amerson EH
Cutis; 2013 Jul; 92(1):35-9. PubMed ID: 23961524
[TBL] [Abstract][Full Text] [Related]
4. Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors.
Deng A; Harvey V; Sina B; Strobel D; Badros A; Junkins-Hopkins JM; Samuels A; Oghilikhan M; Gaspari A
Arch Dermatol; 2006 Feb; 142(2):198-202. PubMed ID: 16490847
[TBL] [Abstract][Full Text] [Related]
5. Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis--data from the dutch arthritis and biologicals in children register, 1999-2010.
Otten MH; Prince FH; Twilt M; Ten Cate R; Armbrust W; Hoppenreijs EP; Koopman-Keemink Y; Wulffraat NM; Gorter SL; Dolman KM; Swart JF; van den Berg JM; van Rossum MA; van Suijlekom-Smit LW
J Rheumatol; 2011 Oct; 38(10):2258-63. PubMed ID: 21844151
[TBL] [Abstract][Full Text] [Related]
6. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
Markenson JA; Gibofsky A; Palmer WR; Keystone EC; Schiff MH; Feng J; Baumgartner SW
J Rheumatol; 2011 Jul; 38(7):1273-81. PubMed ID: 21572150
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of etanercept in chronic immune-mediated disease.
Murdaca G; Spanò F; Contatore M; Guastalla A; Magnani O; Puppo F
Expert Opin Drug Saf; 2014 May; 13(5):649-61. PubMed ID: 24654562
[TBL] [Abstract][Full Text] [Related]
8. Retention on anti-tumour necrosis factor therapy: the Waikato experience.
Ip K; Hartley L; Solanki K; White D
N Z Med J; 2015 May; 128(1415):34-40. PubMed ID: 26117510
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of anti-tumor necrosis factor drugs on health-related quality of life among patients with inflammatory arthritis.
Chen JS; Makovey J; Lassere M; Buchbinder R; March LM
Arthritis Care Res (Hoboken); 2014 Mar; 66(3):464-72. PubMed ID: 24022870
[TBL] [Abstract][Full Text] [Related]
10. Adverse reactions during biological drug therapy in psoriasis:clinical series and a review of the literature.
Montesu MA; Addis GM; Satta R; Cottoni F
G Ital Dermatol Venereol; 2011 Aug; 146(4):273-81. PubMed ID: 21785393
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.
Esposito M; Giunta A; Mazzotta A; Zangrilli A; Babino G; Bavetta M; Perricone R; Chimenti S; Chimenti MS
Dermatology; 2012; 225(4):312-9. PubMed ID: 23295383
[TBL] [Abstract][Full Text] [Related]
12. Anaphylaxis to etanercept in two children with juvenile idiopathic arthritis.
Crayne CB; Gerhold K; Cron RQ
J Clin Rheumatol; 2013 Apr; 19(3):129-31. PubMed ID: 23519173
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of TNF-alpha antagonists in children with juvenile idiopathic arthritis who started treatment under 4 years of age.
Giménez-Roca C; Iglesias E; Torrente-Segarra V; Bou R; Sánchez-Manubens J; Calzada-Hernández J; Hernández S; Ricart S; Antón J
Rheumatol Int; 2015 Feb; 35(2):323-6. PubMed ID: 25086629
[TBL] [Abstract][Full Text] [Related]
14. Potential use of TNF-α inhibitors in systemic sclerosis.
Murdaca G; Spanò F; Contatore M; Guastalla A; Puppo F
Immunotherapy; 2014; 6(3):283-9. PubMed ID: 24762073
[TBL] [Abstract][Full Text] [Related]
15. Tumor necrosis factor inhibitors in the management of juvenile idiopathic arthritis: an evidence-based review.
Shenoi S; Wallace CA
Paediatr Drugs; 2010 Dec; 12(6):367-77. PubMed ID: 21028916
[TBL] [Abstract][Full Text] [Related]
16. Granulomatous disease in a child treated with etanercept.
Alhajri M; Aljumaah S; Aleyouni Y; Al-Qahtani F; Alhazzaa S; Al-Mayouf SM
Int J Rheum Dis; 2013 Aug; 16(4):472-4. PubMed ID: 23826822
[No Abstract] [Full Text] [Related]
17. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis.
Tynjälä P; Vähäsalo P; Honkanen V; Lahdenne P
Ann Rheum Dis; 2009 Apr; 68(4):552-7. PubMed ID: 18467515
[TBL] [Abstract][Full Text] [Related]
18. Etanercept improves lipid profile and oxidative stress measures in patients with juvenile idiopathic arthritis.
De Sanctis S; Marcovecchio ML; Gaspari S; Del Torto M; Mohn A; Chiarelli F; Breda L
J Rheumatol; 2013 Jun; 40(6):943-8. PubMed ID: 23547210
[TBL] [Abstract][Full Text] [Related]
19. Juvenile idiopathic arthritis: current and future treatment options.
Martini G; Zulian F
Expert Opin Pharmacother; 2006 Mar; 7(4):387-99. PubMed ID: 16503811
[TBL] [Abstract][Full Text] [Related]
20. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?
Askling J; van Vollenhoven RF; Granath F; Raaschou P; Fored CM; Baecklund E; Dackhammar C; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Rantapää-Dahlqvist S; Saxne T; Klareskog L
Arthritis Rheum; 2009 Nov; 60(11):3180-9. PubMed ID: 19877027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
